Value Drug Company v. Amneal Pharmaceuticals, Inc. et al
| Filed | 2026-07-27 |
|---|---|
| Court | N.D. Cal. |
| Docket | 3:26-cv-07780 |
| Nature of suit | 410 Anti-Trust |
| Practice area | Antitrust |
| Plaintiff | Value Drug Company |
| Defendant | Amneal Pharmaceuticals, Inc. et al |
| Complaint | Download the complaint (PDF, free) |
What the complaint alleges
Value Drug Company sued Impax Laboratories (and its parent Amneal) and Zydus Pharmaceuticals (and its parent Zydus Lifesciences) in the Northern District of California, alleging that the defendants engaged in an anticompetitive scheme to delay generic competition for the Parkinson's disease drug Rytary. The complaint claims that Impax made reverse-payment agreements with generic manufacturers Actavis and Zydus, including a no-authorized-generic promise and a market-allocation deal, which kept prices artificially high.
Claims asserted
- Sherman Act section 2 - monopolization
- Sherman Act section 1 - conspiracy in restraint of trade
- Sherman Act section 2 - attempted monopolization